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This paper presents the novel domain of evidence-based research (EBR) in the treatment of patients with
Alzheimer’s disease (AD) from the perspective of traditional medicine and of complementary and
alternative medicine. In earlier lectures we have described the process of evidence-based medicine as a
methodological approach to clinical practice that is directed to aid clinical decision-making. Here, we
present a practical example of this approach with respect to traditional pharmacological interventions
and to complementary and alternative treatments for patients with AD.
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Clinical Evidence in Alzheimer’s Disease (AD)
Epidemiological Evidence
Clinical Characteristics—Alzheimer’s disease (AD) is a
progressive disease of the brain. It is a common type of
dementia in the elderly, which can have devastating outcomes
on the diagnosed patient, on the caregiver and family, and on
society at large. Many other conditions can lead to similar
memory loss, confusion, agitation and metabolic disturbances.
Therefore, rushing to give a diagnosis of AD is unwise and is
not common practice. Owing to the absence of an absolute
diagnostic test for AD, diagnosis must depend on observing
trends as the disease evolves over time.
Patients with AD show loss of cognitive, intellectual,
functional and social abilities, and therefore become fully
dependent on their caregiver. It is estimated that in 2010 over
five million people will be diagnosed with probable AD in the
United States alone. Increasing age is the greatest risk factor
for AD; one-tenth of elderly over 65 years of age develop AD,
whereas nearly half of those over age 85 are diagnosed with
probable AD. Certain people in the population are at greater
risk of developing AD due to various genetic risk factors
associated with AD such as apolipoprotein (APO) polymor-
phism. The allele frequency for APO-E4 is significantly higher
in patients with AD compared to control subjects (1). A person
with AD is expected to live an average of 8 years and up to
20 years after the onset of symptoms (1–3).
Psychosocial Concerns—The social and the medical costs to
care for patients with AD are mounting rapidly. National
estimates of annual costs of caring for individuals with AD
today total close to $100 billion (estimates by the Alzheimer’s
Association and the National Institute on Aging), and business
costs approach $61 billion per year in the United States alone.
Over 40% of this budget is dedicated to health care for patients
with probable AD. Among them, 7 out of 10 live at home,
where almost 75% of their care is provided by family and
friends. The remaining 60% of the cost of AD is associated
with expenditures related to caregivers of patients with AD
(e.g. family and friends, nurse and other professional allied
health staff), and include loss of productivity, absenteeism,
worker replacement, etc. (4–6).
About half of all nursing home residents carry the diagnosis of
probable AD, or AD-related dementia. The average cost for
nursing home care is $42 000 per year but can exceed $70 000
per year in some areas of the country, which leads to an
estimation of $174 000 for the average lifetime cost of care for a
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to a large extent, the Federal government estimated spending
approximately $640 million for AD research in fiscal year 2003
alone. An accurate diagnosis is a key factor in insuring the
highestbenefittothepatientandthecaregiver,whileminimizing
the cost.
Biomedical Evidence
Neuropsychopathology—Since ancient times, it has been clear
that some people lose mental sharpness (cognitive function) as
they age. It was in 1906 that AD was first described by Alois
Alzheimer (1864–1915) in an autopsy on the brain of a 56-
year-oldwoman, Augusta D. of Frankfurt.Ms D. had died after
several years of progressive mental deterioration marked by
increasing confusion and memory loss. The German neurol-
ogist described an odd disorganization of the nerve cells in Ms
D.’s cerebral cortex, the part of the brain responsible for
reasoning and memory. The cells contained clusters suggestive
of a rope tied in knots. Alzheimer named them ‘neurofibrillary
tangles’. There also was an unexpected accumulation of
cellular debris around the affected nerves, which are now
recognized as the ‘senile plaques’. Alzheimer speculated that
the nerve tangles and plaques were responsible for the
woman’s dementia (7). Several independent cases soon
revealed similar patterns, which led the German psychiatrist
Emil Kraepelin (1856–1926) to name the disease in honor of
his mentor.
AD progressively destroys the ability to reason, remember,
imagine and learn—We now know that in AD, tangles and
plaques eventually take over healthy brain tissue, devastating
the areas of the brain associated with intellectual function, and
progressively destroying the ability to reason, remember,
imagine and learn. AD characteristically is a progressive
condition marked, at its onset, by simple forgetfulness of
instances such as recent events, telephone numbers or
directions to familiar places. Patients with AD experience
personality changes, such as poor impulse control and
judgment, distrust, increased stubbornness and restlessness.
The disease progresses into difficulty in executing tasks that
require planning, decision-making and judgment, such as
working, balancing a cheque book or driving a car. A person
with probable AD typically has trouble finding the right word,
and often substitutes unusual words, making comprehension
of speech or writing difficult. It is quite common for a person
with probable AD to become confused or lost in a familiar
neighborhood, to demonstrate poor or decreased judgment
about social behavior, clothing, money and abstract thinking.
A person with probable AD may misplace items, and put
them in unusual places (e.g. placing a writing pen in the
freezer). Patients with probable AD may show rapid mood
swings, personality changes, confusion, suspicious behavior,
fearfulness, anger, or dependence on a family member or
caregiver. They may become passive, apathetic and uninter-
ested in performing usual activities.
Post-mortem examination reveals two abnormal structures
in the brain associated with AD. Amyloid plaques are clumps
formed by the b-amyloid protein (Ab; 42 amino acids) that
accumulate outside of cells. Neurofibrillary tangles are clumps
of altered t (tau) proteins inside cells. Although it is known
that these structures are toxic to neurons, the exact role plaques
and tangles play in the onset and progression of AD-dementia
is not fully determined (2,8–10).
Progression of AD-dementia symptoms corresponds in a
general way to the underlying neuronal cell degeneration that
takes place in AD. Nerve cell damage typically begins with
cells involved in learning and memory, and gradually spreads
to cells that control every aspect of thinking, judgment and
behavior. Neuropathology eventually impairs cells that control
and coordinate movement.
Apoptosis(programmedcelldeath)maybethemechanismof
neuronaldeathinADsinceDNAfragmentation, cell shrinkage,
membraneswellingandcaspaseactivationalloccurininvolved
neurons. Ab appears to be one, if not the main trigger of
neuronal apoptosis, and extracellular Ab has been shown to
activate c-Jun-N-terminal kinase, which leads to transcription
of Fas ligand (FasL). The binding of FasL to Fas leads to
caspase activation, which directs the apoptotic process. Ab also
induces apoptosis of lymphocytes, and renders phagocytic cells
of innate immunity unresponsive (11–18).
Clinical Evidence
Disease Progression and Stages of Social Withdrawal—
Everydayskills,suchaspersonalgroomingoralifelonghobby,
are eventually affected, gradually leading to social withdrawal.
Simple tasks of independent daily living (e.g. eating, bathing,
using the toilet) become impossible, and patients often lose
interest in personal hygiene and appearance, as well as social
sexual inhibitions. Communication of all kinds becomes
difficult as written and spoken language ability dwindles.
Withdrawal from family members often occurs as patients at
this stage become agitated, belligerent and deny the illness.
At the later stage of the disease, patients are mostly bedridden,
and await death, which results from pneumonia or related
complications. In brief, signs of clinical impairment include
changes in memory, which are normal in aging, but that are
exacerbated in patients with probable AD by symptoms of
difficulties in communicating, learning, thinking and reason-
ing. These symptoms are severe enough to impact the person’s
work performance, social activities and family life. (3,19–21).
Staging provides useful frames of reference for the process of
diagnosis—The diagnosis of probable AD is obtained by
clinical assessment.Earlydiagnosispermitstime tomake choices
that maximize quality-of-life, lessens anxieties about unknown
problems, provides a better chance of benefiting from treatment
and allows more time to plan for the future (3,19,21–25).
Staging systems have been developed to provide useful
frames of reference for the process of diagnosis by exclusion,
and for understanding how the disease unfolds, and for clinical
decision-making. It is recognized that the stages are artificial
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one person to another. Nevertheless, the Global Deterioration
Scale andothersimilar instruments have proventobeareliable
diagnostic system to generate clinical evidence toward an
outline of key symptoms characterizing seven stages ranging
fromunimpairedfunctiontoveryseverecognitivedecline(21).
Agitation Often Reflects an Underlying Infection or Medical
Illness—Above and beyond the general symptomatology, a
person with probable AD typically manifests what is commonly
referred to as agitation. In the early stages of the disease,
agitation accompanies memory loss, thinking problems,
personality changes, irritability, anxiety, depression, sleep
disturbances, delusions (firmly held belief in things that are
not real), hallucinations (seeing, hearing or feeling things that
are not there), pacing, repetitive and restless movement, general
emotional distress, and cursing or threatening language.
Agitation often reflects an underlying infection or medical
illness, pain or discomfort, including loss of hearing or
eyesight. Prescription medications for the treatment of AD-
associated or non-AD dementias can cause agitation, espe-
cially when multiple medications are used. Agitation may be
exacerbated by drug interactions, or by circumstances that
worsen the person’s ability to think, including moving to an
unfamiliar environment or variable caregivers. Agitation can
disrupt patient care, and interfere with the ability of the patient
or the caregiver to carry out activities of independent daily
living. The treatment of agitation depends on a careful
diagnosis, determination of the possible causes and the types
of agitated behavior the person is experiencing. With proper
pharmacological treatment and intervention, significant reduc-
tion or stabilization of the symptoms can often be achieved
(21,26,27). Atypical anti-psychotic and anti-convulsant med-
ications with mood-stabilizing properties are most commonly
used to treat agitation (20,25,27–30).
Treatment of Patients with AD
Traditional Pharmacological Intervention for Patients
with AD
Pharmacological Interventions—There is no cure for AD, but
several drug treatments are available that improve or stabilize
symptoms. Certain strategies and activities may minimize or
prevent behavioral problems. Early initiation of treatment can
delay the need for nursing home care.
Current interventions for AD include acetylcholinesterase
inhibitors (AchI), which are indicated for patients with mild to
moderate symptoms. Treatment with memantine interferes
with the glutamate neurotransmitter receptor system and is the
sole intervention recommended for moderate to severe cases of
AD. A spectrum of alternative treatments for AD has also been
proposed, and must be examined judiciously in preclinical,
clinical and evidence-based research (EBR) studies.
The US Food and Drug Administration (FDA) has approved
drugs to treat cognitive symptoms of AD. Cholinesterase
inhibitors [donepezil (Aricept ), approved in 1996; rivastigmine
(Exelon ), approved in 2000; galantamine (Reminyl ),
approved in 2001; and tacrine (Cognex ), approved in 1993],
aim at inhibiting cholinesterase, the enzyme in brain neurons that
regulates the levels of acetylcholine. The drugs keep levels of the
chemical messenger high, even while the cells that produce the
messenger continue to die. About half of the patients who take
cholinesterase inhibitors experience a modest improvement in
cognitive symptoms. Patients who receive tacrine may suffer
from serious side effects, including liver damage (21).
Memantine–HCl (aka, Namenda
TM) was FDA-approved in
October 2003. It has a reported effectiveness for the treatment
of moderate to severe AD. Memantine was tested in two
placebo-controlled Phase III clinical trials in the United States,
and one earlier trial in Europe. Typically, patients treated with
memantine scored higher on measures of cognition, daily
function (i.e. activities of daily living such as eating, walking,
toileting, bathing and dressing) and global performance, with
limited side effects (dizziness, confusion, headache and
constipation), compared to those on placebo. Memantine has
a mechanism of action distinct from other approved treatments
for AD, which, as noted, are acetylcholinesterase inhibitors
and are indicated for the treatment of mild to moderate AD. In
contrast, memantine is a low-affinity antagonist for N-methyl-
d-aspartate (NMDA) receptor, which binds the neurotransmit-
ter glutamate. Glutamate plays an integral role in the neural
pathways associated with learning and memory. Abnormal
levels of glutamate may lead to neuronal cell dysfunction, and
memantine may blunt these deleterious effects (21,30,31).
Pharmacological Side Effects—Medications given to patients
with probable AD-related dementia increase the risk for tooth
root caries and periodontal disease due to the drugs’ side
effects. For example, the anti-convulsant drug phenytoin can
cause gingival hyperplasia specially in the presence of plaque,
while many antipsychotic agents such as phenothiazines
used to control behavioral problems, especially aggression
and emotional instability, can cause xerostomia, a lack of
saliva (32).
Complementary and Alternative Intervention in AD
Certain herbal remedies and alternative dietary supplements
have been suggested as effective treatments for AD. Claims
about the safety and effectiveness of these products lack
scientific proof. Concerns about these alternative strate-
gies include lack of knowledge and assurance about
safety, purity, side effects and potential interactions with
prescribed medications. Supplement or alternative treat-
ment should not be recommended without consulting a
physician.
CAM and Anti-Oxidants such as Gingko biloba May Protect
Cell Membranes from Inflammatory Processes—Among the
alternative treatments, Ginkgo biloba, a plant extract rich in
compounds that may have positive effects on cells within the
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anti-inflammatory properties. Thus, it may protect cell
membranes from inflammatory processes associated with
plaque and tangle formation (vide infra), and help regulate
neurotransmitter production, function and metabolism.
Research has established no measurable difference, however,
in the overall benefit in patients with probable AD treated with
this traditional Chinese medicine (TCM) herb (33). Although
few side effects are associated with its use, it may reduce the
ability of blood to clot, and thus lead to serious internal
bleeding, when taken in combination with aspirin or warfarin
(34–36). The moss extract, Huperzine A, is also not FDA-
approved, and appears to mimic cholinesterase inhibitors. It
has not been associated with risks of serious side effects to date
(37). Finally, it has been proposed that ‘Coral’ calcium
supplements may be a cure for AD, because it is a form of
calcium carbonate derived from the shells of formerly living
organisms that once made up coral reefs, and hence rich in
other minerals. Research has failed to support these claims to
date (21).
Promising Alternative Strategies for AD Involve Preventing
Neuronal Toxicity—Phosphatidylserine is one among the many
specialized lipidsin neuronal cell membranes. Giventhefact that
neurons degenerate in AD, the strategy behind phosphatidylser-
ine dietary supplements is to prevent neuron toxicity and death
by providing excess of this lipid. Results of clinical trials to date
appear encouraging, but larger carefully controlled trials are
needed to determine the viability of this treatment (38). In
addition, the natural antioxidant coenzyme Q10 (i.e. ubiqui-
none), required for normal ‘household’ cell metabolism, is under
testing as well. Its synthetic equivalent, idebenone, when tested
in clinical trials with patients with AD, failed to show favorable
results.
Alternative treatments are based on the observation that AD
develops and progresses as a result of the production of the bA
protein. Since accumulation of this protein is associated
with oxidative and inflammatory damage, promising alter-
native strategies for treating patients with AD involve the use
of anti-oxidants (e.g. vitamin E) and anti-inflammatory drugs.
Ecam and Preventing Cognitive Decline—It has long been
recognized that patients with AD present an irreversible
decline of cognitive functions as a consequence of cell
deterioration in the forebrain cholinergic projection system.
It is now believed that the reduction of the number of
cholinergic cells at this cerebral site disrupts not just its
functions locally and direct connections, but also significantly
alters the modulation of related systems, leading to inter-
ference in several aspects of behavioral performance, arousal,
attention, learning and emotion (39–41). Therefore, concerted
efforts in alternative treatments for this condition have used
supplements of choline.
In brief, given the fact that patients with AD will present an
ever-increasing fiscal onus to society as their number climbs to
over 10 million in the United States in the next decade, it is
imperative to develop, test and establish successful treatment
interventions. It is also evident that supplementing current
pharmacological treatment (i.e. cholinesterase inhibitors) with
alternative medicine, a popular trend in the current ‘self-help’
societal paradigm requires stringent and rigorous control, such
as that provided by evidence-based medicine (EBM).
EBR in the Treatment of Patients with AD
As noted before, EBR is the break-open avenue for future
research in the health sciences in general and in AD preclinical
and clinical research in particular (42). Systematic research on
research seeks to establish and to determine what is the best
available evidence for treatment for each individual patient.
This critical approach is key particularly in the case of AD,
when one considers the sharp rise in the aging population and
the subjects at-risk for AD in the next decades, in relation to
the often under-tested, unreliable and sometimes unfounded
‘popular’ alternative treatments. EBR, which is the best tool
presently to examine systematically the strength of clinical
data to mold, as it were, novel and improved modes of
intervention to meet the criteria of excellence we demand for
the benefit of the patients.
Reviewing the Evidence about Pharmacological
Intervention
Due to the rising number of patients with AD, several modes of
treatment interventions exist. In general, two among the
pharmacological treatments have shown more promising
results in treating AD: acetylcholinesterase inhibitors (AChI)
and NMDA antagonists (30,42).
Stating the Question—A best-case study was designed to
evaluate the current published literature on both AChI and the
NMDA antagonist (memantine). The PICO question was
formulated as follows: in a patient population over the age of
45, with moderate AD, are acetylcholinesterase inhibitors the
treatment of choice over NMDA antagonists, in effectively
increasing the quality-of-life? The outcome of interest,
quality-of-life, was measured based on three domains of AD
that are known to deteriorate as the disease progresses and
worsens:
(i) Cognitive function,
(ii) Global performance and
(iii) Activities of daily living.
Obtaining the Sample—The search was restricted to articles
relevant to the PICO question within the PubMed Database.
Only articles in English were considered, and authors were not
contacted regarding original data. Review articles, abstracts,
unpublished reports and publications in press were not
considered. The search used a combination of the search terms
‘moderate Alzheimer’s disease’, ‘Alzheimer’s disease’, ‘acet-
ylcholinesterase inhibitors’, ‘daily living’, ‘quality of life’,
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‘galantamine’, ‘memantine’ and ‘treatment’. The search was
limited to clinical trials, and to subjects between the ages of
45–64.
The titles and abstracts of all published articles obtained
from this search were examined in order to determine if it were
applicable to the study’s purpose/PICO question. An initial
screening was carried out based on the following inclusion
criteria:
(i) The study was a clinical trial published in the English
language.
(ii) Patients met the criteria for AD-associated dementia
[as per Diagnostic and Statistical Manual of Mental
Disorders, 4th edition (DSM-IV)], and/or the prob-
able AD criteria based on the National Institute of
Neurological and Communicative Disorders and
Stroke-Alzheimer’s Disease and Related Disorder’s
Association [reports of patients with other dementias
(e.g. vascular dementia) were excluded].
(iii) Patients were older than 45.
(iv) Treatment fell in either one of the two categories:
acetylcholinesterase inhibitors or NMDA antagonists.
(v) Quality-of-life was assessed in one or more of the
three given domains of AD—cognitive function,
global performance and activities of daily living.
Men and women were included, as well as patients of any
race and/or ethnicity.
Using the PubMed database, the search conducted brought in
an initial lot of 1721 papers. Of these papers, 168 articles
were clinical trials published in the English language, with
subjects falling in the age range of 45–64 (as specified in the
advanced search/limitations of PubMed). As described, a
screening was done to filter out trials failing to meet the
inclusion and exclusion criteria of the search strategy. These
1721 citations obtained from search
168 Clinical Trials in English language,
             with age range over 45 years old-
1553 Excluded Irrelevant Studies
22 Potentially Eligible Studies
146 Excluded Studies, as screened by
the inclusion/exclusion criteria
9 Excluded from best-case study-
           2 Reviews
           3 Treatment was of mixed therapies not
                  relating to AChI or NMDA antagonists
4 Papers could not be retrieved in given time
13  Studies Included in best-case study -
                  12 Acetylcholinesterase  Inhibitors
                  1  NMDA Antagonist
Scheme 1. Search Process: flow diagram of included and excluded studies. A search for relevant studies was performed using the PubMed database, and
subsequently filteredout based on the inclusion/exclusion described. Thirteen reports (12 acetylcholinesterase inhibitorsand 1 NMDA antagonist) were included in
the best-case study examining pharmacological interventions for AD, and thus evaluated individually on its quality.
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(Scheme 1). A final lot of 13 papers were included in this
best-case study (31,43–54).
Critical Evaluation—Reports were evaluated for quality of
methodology, design and data analysis by the Wong Scale-
Revised, and the data analyzed statistically (Analyze-It,
version 1.72) (Fig. 1 and Table 1). This scale is based on
reviewer responses of nine questions concerning the research
quality of each individual paper; with a score of 1, 2 or 3 (best)
provided for each query, as well as a comprehensive total score
ranging from 9 to 27) (55). Papers falling under a total Wong
score of 18 indicates that the quality of the methodology,
design and data analysis fail to support the reliability of the
author’s conclusions and were thus omitted from the evidence
supporting a consensus statement. This ‘acceptable sampling’
approach aims to determine whether the papers examined are
acceptable, based on the features posed by the Wong Scale-
Revised (42).
The literature regarding treatment of AD by the two modes
of pharmacological intervention under comparison was reli-
able [mean ± standard deviation attribute score (i.e. total Wong
scale score) of 18.75 ± 2.09; 95% CI ¼ 17.67–20.33]. Three
papers obtained a total Wong scale score of less than 18;
implying that the quality of the methodology, design and data
analysis of these few papers failed the minimum cut-off
requirement of acceptability. Further analysis of the scores led
to the establishment of criterion of acceptability for each of the
individual domains of research assessed by the Wong scale.
Analyses Indicate that an AChI or NMDA Antagonist Was
Beneficial in Terms of Increasing Patients’ Overall Global
Performance—Following the acceptable sampling analysis,
meta-analyses were conducted (BioStat Comprehensive Meta-
Analysis software, version 1.0.25). Studies, which provided
descriptive statistics, were used to calculate the effect size for
the meta-analysis. Therefore, those papers that failed to
report exact statistical values (mean ± SD) were omitted.
Five trials provided data on 1033 patients with mild to
moderate AD, aged 45 or older (422 patients randomized to the
treatment group and 611 to the placebo group). Duration of
treatment also varied among the studies. One trial reported
testing the NMDA-antagonist memantine, whereas the remain-
ingfourinvestigatedacetylcholinesterases:tacrine(onereport),
galantamine (one report) and rivastigmine (two reports).
The AchI eptastigmine has not yet been fully approved by the
US FDA, and was thus excluded from the analysis.
A meta-analysis was carried out analyzing the AD assess-
ment scale—cognitive subscale (ADAS-cog) as the outcome
measure. This test assesses cognition based on various fields,
suchasmemory,language,orientationandpraxis(56).Another
meta-analysis was performed on the results obtained from the
Clinician Interview Based Impression of Change Scale plus
caregiver information (CIBIC-plus). This assesses the global
performance of AD patients, based specifically on changes
occurred due to the treatment (57) (Table 2). The over-
whelming findings of these analyses indicate that all treat-
ments, whether an AChI or NMDA antagonist, were beneficial
in terms of increasing patients’ overall global performance,
assessed as ADAS-cog (Fig. 2A), or as CIBIC-plus
(Fig. 2B). Our data also indicate that AchI compared more
favorably than mean time with respect to the CIBIC-plus
treatment outcome of global performance (Fig. 2B).
Reviewing the Evidence about Complementary and
Alternative Treatment
Stating the Question—By the same approach we formulated a
PICO question with respect to complementary and alternative
treatment for patients with AD. In brief, it stated that ‘in a patient
population over the age of 45 with moderate AD, are antioxidants
more effective in increasing the quality-of-life than no treatment?’
The outcome of interest (quality-of-life) was measured based on
three domains of AD
(i) Cognitive function,
(ii) Global performance and
(iii) Activities of daily living.
Obtaining the Sample—As above, this search was restricted to
articles relevant to the PICO question within the PubMed
database. Authors were not contacted regarding original data.
Review articles, abstracts, unpublished reports and publications in
Figure 1. Wong Scale-Revised. The Wong Scale-Revised consists of nine
questions used to evaluate the quality of a study. Once applied, various scores
are generated that determine the validity of the paper based on a scale of 1–3,
with 1 ¼ inappropriate, 2 ¼ mediocre, 3 ¼ appropriate. A comprehensive
score falls in the range of 9–27 points. Studies whose scores sum a total of 18
or less are rejected while those scoring 19 or over are accepted [modified
from (21)].
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tion of the following terms: ‘moderate Alzheimer’s disease’,
‘Alzheimer’s disease’, ‘treatment’, ‘antioxidants’, ‘daily living’
and ‘quality of life’. The search was limited to clinical trials and to
subjects between the ages of 45–64; as indicated by the limited/
advanced search feature of the PubMed database. The titles and
abstracts of all published reports obtained from the PubMed
search were further examined in order to determine its
applicability to the study’s aim. The literature was screened to
filter out all irrelevant papers based on the same inclusion/
exclusion criteria as mentioned in the previous example. In this
example, however, antioxidants were used as the active treatment
rather than AChI or NMDA antagonists.
The search was conducted and initially provided a lot of
1014 papers to be screened according to the criteria previously
described. A total of 985 papers were excluded due to their
irrelevancy to the PICO question. Of the papers remaining,
there were 29 potentially eligible studies, which were further
examined using the exclusion/inclusion criteria. Ultimately,
the majority of the published studies on antioxidants was
eliminated from this study largely because most samples
were not exclusively AD patients, and included other types
of dementias (e.g. vascular dementia). The 11 studies that
met the exclusion/inclusion criteria of this best-case study are
listed in Table 3 (58–68). The search process is represented in
Scheme 2.
Critical Evaluation and Analysis and Interpretation—As
previously described, each individual paper was then evalu-
ated entirely for its quality on methodology, design and data
analysis by the implementation of the Wong Scale-Revised
(42) (Fig. 1); followed by statistical analysis, as above, using a
one-way ANOVA (Analyse-It, version 1.72). All papers were
critically examined, and rated by one trained evaluator. Scores
and statistical analysis are shown in Table 3. Two of the papers
received a score falling below the cut-off score of 18 and were
therefore rejected. The conclusions of these two studies were
not included in the evidence supporting the consensus
statement. Only 9 out of the 11 papers (84.6%) were included
in the generation of the consensus statement.
Table 1. Acceptable sampling analysis of pharmacological interventions: acetylcholinesterase inhibitors and NMDA antagonists
Paper Question Wong Scale Total
What A What B What C Who A Who B Who C How A How B How C
1 3.00 3.00 2.00 2.00 2.00 3.00 2.00 2.00 3.00 22.00
2 3.00 3.00 2.00 1.00 3.00 2.00 3.00 2.00 2.00 21.00
3 2.00 2.00 3.00 1.00 2.00 2.00 1.00 2.00 3.00 18.00
4 2.00 3.00 3.00 2.00 1.00 3.00 2.00 1.00 2.00 19.00
5 2.00 3.00 2.00 2.00 2.00 3.00 1.00 3.00 2.00 20.00
6 2.00 3.00 2.00 1.00 1.00 1.00 2.00 2.00 1.00 15.00
7 2.00 3.00 2.00 2.00 1.00 3.00 2.00 2.00 2.00 19.00
8 2.00 2.00 2.00 1.00 2.00 3.00 3.00 2.00 3.00 20.00
9 1.00 2.00 2.00 2.00 2.00 3.00 1.00 1.00 1.00 15.00
10 2.00 3.00 2.00 1.00 2.00 2.00 2.00 3.00 3.00 20.00
11 2.00 2.00 1.00 1.00 1.00 2.00 3.00 2.00 3.00 17.00
12 2.00 3.00 3.00 2.00 1.00 3.00 1.00 2.00 3.00 20.00
13 3.00 3.00 2.00 2.00 1.00 3.00 2.00 2.00 3.00 21.00
Mean 2.15 2.69 2.15 1.54 1.62 2.54 1.92 2.00 2.38 18.75
SD 0.55 0.48 0.55 0.52 0.65 0.66 0.76 0.58 0.77 2.09
95% CI 1.82–2.49 2.40–2.98 1.82–2.49 1.23–1.85 1.22–2.01 2.14–2.94 1.46–2.38 1.65–2.35 1.92–2.85 17.67–20.33
P
Strong evidence What B, Who C 0.503
Adequate evidence How C 1.000
Moderate evidence What A, What C,
How B
0.495
Weak evidence Who A, Who B, How A 0.14
Variation SSq DF MSq FP Coefficient P
ANOVA analysis of Wong scores Distribution of total scores
Paper 15.86 8.00 1.98 5.14 <0.0001 Shapiro-Wilk 0.8977 0.1245
Within cells 41.69 108.00 0.39 Skewness  0.8341 0.1676
Total 57.56 116.00 Kurtosis  0.1145 –
Scores obtained from the Wong Scale-Revised were statistically analyzed using a one-way ANOVA. Data were used to determine the acceptability of the
13 applicable studies as a whole.
eCAM 2006;3(4) 417This best-case study shows that the available literature
regarding the treatment of AD using antioxidants compared to
no treatment was reliable [mean ± SD attribute score (i.e. total
Wong scale score) of 19.55 ± 2.02; 95% CI ¼ 18.19–20.90).
This is further supported by the fact that the majority of
included papers received a total attribute Wong score above
the cut-off line of 18 (only two studies were omitted).
Additional analysis of the scores, as examined for each
domain of the Wong Scale-Revised (42), indicates both
adequacies and deficiencies in the satisfaction of the queries
addressed.
Five trials provided enough data to run a meta-analysis
examining the outcome of the quality-of-life in Alzheimer’s
patients. It was necessary that quality-of-life (outcome
measured) was assessed in one or more of the three given
domains of AD (cognitive function, global performance and
daily living activities) using the appropriate psychometric tests
described in Table 4. Data were provided for 1017 patients
with mild to moderate AD, aged 45 or older; with 650 patients
randomized to the antioxidant treatment group and 367 to the
placebo group. The duration of treatment varied from study to
study, ranging from 24 weeks to 12 months; with the majority
reporting data for  24 weeks. In this meta-analysis, four
studies tested an extract of Gingko biloba referred to as EGb
761, while one report examined the efficacy of idebenone (a
compound of the antioxidant coenzyme Q10).
Meta-analyses were conducted (BioStat Comprehensive
Meta-Analysis software, version 1.0.25) using data from the
Alzheimer’s Disease Assessment Scale-cognitive subset
(ADAS-cog) and Syndrom–Kurztest, also known as the Short
Cognitive Performance Test (SKT). The Syndrom–Kurztest
test focuses on the patient’s cognitive performance as well.
This test has been shown to be validated to measure attention
and memory functions (69).
The literature shows that the effect of antioxidant treatment
for mild to moderate AD on cognitive function, as it was
assessed by the ADAS-cog scale and SKT, support the use of
antioxidants. Moreover, from these results, there is promising
evidence to speculate the potential benefits of Ginkgo biloba
as a treatment option. More clinical trials need to be performed
on both Ginkgo biloba and idebenone to determine their
advantages and treatment effects.
Consensus Statement
Traditional Treatment of Choice for Moderate AD Is AChI
Inhibitors, in Terms of QOL
AD is a devastating disorder of the brain’s nerve cells that
impairs memory, thinking and behavior, which leads, ulti-
mately, to death. Its certain diagnosis can be secured by post-
mortem brain biopsies only, and diagnoses obtained from
inpatients before death are best reported as ‘probable AD’.
Accuracy of pre-morbid diagnosis approximates 90%. The
impact of the disease on individuals, families and our health
care system makes AD one of the greatest medical, social and
fiscal challenges for the 21st century.
Taken together, the best available evidence derived from the
best-case study examining pharmacological interventions
suggests that the treatment of choice for individuals with
moderate AD is AChI inhibitors, over NMDA antagonists, in
terms of quality-of-life. This evidence-based analysis also
uncovered the fact that adverse effects occurred as a result
of each treatment, which may affect the overall tolerability of
the drug.
Studies and research on memantine (the only NMDA
antagonist approved by the US FDA as of yet) is rather new
compared to the drugs classified as AChI. Thus, it is not
surprising that there exist a larger number of reports on AChI
versus that of NMDA antagonists. This imbalance, unfortu-
nately, may create a selection bias in the analytical aspects of
this best-case study. It is therefore self-evident that, as more
studies are conducted on the efficacy of various drugs for the
treatment of AD, the consensus statement will require regular
revisions and updates with the inclusion of the latest available
evidence.
CAM Intervention: Antioxidant Treatment for Mild to
Moderate AD Potentially Increases QOL
From the viewpoint of CAM, the best-case study presented
here in the context of complementary and alternative
intervention in patients with AD attempts to present the
Table 2. Instruments for assessing quality-of-life in patients with AD
Domains
assessed
Instrument Source Scale
Cognitive
function
Alzheimer’s disease
assessment scale
(cognitive)—ADAS-cog
Patient 0–70 points
0 ¼ no errors
70 ¼ severe
impairment
Cognitive
function
Syndrom–Kurz
test (SKT)
Global
performance
Clinician Interview
based Impression
of Change Scale
(plus caregiver
information)
CIBIC-Plus
Patient and
caregiver during
interview with
clinician
1–7 points
1, 2, 3 ¼ marked,
moderate, or
improvement
4 ¼ no change
5, 6, 7 ¼ minimal,
moderate or
marked
deterioration
Activities of
daily living
Progressive
Deterioration
Scale (PDS)
Caregiver 29 items, with
a score range of
0–100
100 ¼ less able
to carry out
activities of
daily living
Activities of
daily
living
Geriatric Evaluation by
Relative’s Rating
Instrument (GERRI)
Caregiver
The three domains of quality-of-life (cognition, global performance, activities
of daily living) were assessed by the ADAS-cognitive scale, SKT, CIBIC-Plus,
PDS and GERRI tests. Meta-analyses were generated using the results of the
five stated tests.
418 Evidence-Based Research in Alzheimer’s Diseaseoverall reliability of the best available evidence related to
treating AD with the use of antioxidants. This approach is
more complementary when compared with the more tradi-
tional pharmacological therapies (acetylcholinesterase inhibi-
tors and NMDA antagonists). It is important to note also that
other substances having antioxidant activity do exist, and have
been studied in relation to AD, but simply have not been
included due to the criteria of this study. Furthermore, there is
an extensive area of treatments categorized as CAM such as,
massage, acupuncture, trans-cutaneous electric nerve stimula-
tion, music therapy, counseling, psychotherapy and exercise
that were not studied in this best-case study.
Via the ‘acceptable sampling’ technique (42), the given
lot of 11 papers were analyzed for their research quality, and
the best available evidence from these studies indicates that at
this moment there is no precise answer to whether the use of
antioxidants should be used to treat patients with AD. Overall,
the effect of antioxidant treatment compared with no
treatment is beneficial; as based on the ability of this therapy
approach to increase the quality-of-life in the three domains of
cognition, global performance and daily living functioning.
However, doubts about the effectiveness of idebenone are
evident in the literature (68). The meta-analyses conducted
supports the use of antioxidants compared with no treatment in
terms of data obtained from the SKT, as well as when
examining data from the ADAS-cognitive scale (Fig. 3A and
3B). It is important to note though that the studies included in
the meta-analyses examined the effects of Ginkgo biloba in
four reports, versus idebenone, which constituted data
from one report. This difference potentially creates a selection
bias in the analysis of the data. Moreover, a large number of
the studies using antioxidants as a form of complementary
and alternative medicine assessed a sample of patients with a
wide range of dementia, and thus were not included in this
best-case study as determined by the inclusion/exclusion
criteria.
Taking the results from both approaches utilized, the
CAM best-case study suggests that antioxidant treatment for
individuals with mild to moderate AD does have the potential
to beneficially increase quality-of-life, although there are
some reports that disagree. Evidence also revealed that the
side effects observed were minor: mainly consisting of
headaches, nausea, insomnia and anxiety. Furthermore, no
detrimental consequences such as a decrease in the quality-of-
life occurred as a result of antioxidant administration. The use
of antioxidant treatment appears to have a positive outcome,
although it is clear that more clinical trials need to be carried
out in order to fully support the use of antioxidants as a
primary treatment for AD. Other concerns that must be
addressed by clinical trials should also examine its potential
reaction with other modes of interventions, including already
established pharmaceuticals.
Limitations
The research approach performed in this best-case study
exemplifies the importance of critically analyzing the evidence
available, such that one can determine if the results presented
are trustworthy to support clinical actions to improve the status
of the patient. As a result, the consensus statement must be
regularly updated to represent a culmination of all of the newly
published literature.
A
B
Citation N1 N2 Effect NTotal PValue
50 21 20 6.843 41 .000
51 28 116 .179 144 .393
53 119 186 .597 305 .000
55 157 205 2.531 362 .000
Fixed Combined (4) 325 527 1.261 852 .000
-8.00 -4.00 0.00 4.00 8.00
Favors No Treatment Favors Treatment
Meta Analysis: ADAS-Cognitive
Citation N1 N2 Effect NTotal PValue
31 97 84 .266 181 .075
50 21 20 1.997 41 .000
55 155 197 1.540 352 .000
Fixed Combined (3) 273 301 1.084 574 .000
-4.00 -2.00 0.00 2.00 4.00
Favors No Treatment Favors Treatment
Meta Analysis: CIBIC-Plus
Figure 2. (A) Results from meta-analysis of ADAS-cognitive outcome (assessment of cognition) for pharmacological interventions (acetylcholinesterase
inhibitors versus NMDA antagonists). A meta-analysis was carried out to evaluate the efficacy of AChI and NMDA antagonists in increasing the cognitive
performance of patients with Alzheimer’s disease, based on ADAS-cognitive scores. All four studies favored the active treatment over placebo. (B) Results from
meta-analysis of CIBIC-Plus score (assessment of global performance) for pharmacological interventions best-case study (acetylcholinesterase inhibitors versus
NMDA antagonists). A meta-analysis was carried out to evaluate the efficacy of AChI and NMDA antagonists in increasing the global performance of patientswith
Alzheimer’s disease, based on scores obtained from CIBIC-Plus. All three studies favored the active treatment over placebo.
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420 Evidence-Based Research in Alzheimer’s DiseaseAs with every methodology, biases and problems exist in
EBR in medicine. Not possessing the capacity for critical
analysis of the research methodology would preclude correct
data analysis, ultimately preventing appropriate decision-
making in the clinical realm (70). Specifically in the context
of the topic of this paper, systematic review of the literature,
one of the tenets of EBM, can show biases and limitations: the
review parameters may be incorrectly or poorly drawn, thus
affecting conclusions and findings (71).
The process of systematic review of the research
evidence, the raison d’e ˆtre of EBM, is a process of critical
research on research. As we noted above, the merit and
strength of EBM lies in the rigor of its scientific method,
and in the quality and clinical use of its product. The
product of this process is valuable firstly because it
identifies the best available evidence for intervention, and
secondly because it generates a cost-effectiveness analysis,
which is a process of decision analysis that incorporates
risks as well as cost. Effectiveness and utilities of these
clinical data and information are estimated to aid the final
clinical decision-making process for the benefit of each
individual patient. However, in order to be reliable, the
EBM outcome for any given clinical condition needs to be
updated at regular 6–12 month intervals (42). The challenge
of staying current with the ever-changing literature field can
be aided by the tools provided by EBM, such as critically
and systematically appraising evidence, and incorporating it
into clinical practice (72). In short, it can be argued that
guiding clinical practice by EBM postulates is necessary to
improve quality of care by the utilization of efficacious
methods, and by extension, the elimination of the ineffective
and harmful ones (73).
Divergent findings could suggest fundamental methodolo-
gical issues, which may lead to substantial misinterpretations
in the meta-analyses. In a fixed-model meta-analysis, the
assumption is that there is some overall common difference
that can be estimated. In order to test for homogeneity. To test
this assumption, the Q or the I
2 statistics often ensure that the
population difference is the same across all the studies. Neither
test was applied in the analyses described above, thus ignoring
potential differences among the studies, such as population
differences that may not be constant across the studies (i.e.,
random-model). Another caveat of these analyses is the
pervasive inherent bias (cf., ‘‘publication bias’’) we identified
but could not explore in depth due to the paucity of the
available reports. A useful graphical representation of this bias
1014 citations obtained from search of 
PubMed Database using search terms
985 Excluded Irrelevant Studies, as screened
by inclusion/exclusion criteria
29 Potentially Eligible Studies
18 Excluded from best-case study
 1    Review
  5  Treatment not related to antioxidants
  3  Papers could not be retrieved in given time
  5  Outcome was not measuring ‘quality of life’
  4  Sample included patients of mixed dementia
11 Studies included in best-case study
 5    Gingko  Biloba
  5  Idebenone (Co-Enzyme Q10)
 1    Alpha-tocopherol
Scheme 2. Search Process: flow diagram of included and excluded studies. A search for relevant studies was performed using the PubMed database, and
subsequently filtered out based on the inclusion/exclusion described. Eleven reports (5 Ginkgo biloba, 5 idebneone and 1 alpha-tocopherol) were included in the
best-case study examining antioxidants as a treatment for AD, and thus each study was evaluated individually on its quality.
eCAM 2006;3(4) 421could have been the traditional funnel plot, in which the
magnitude of the effect is plotted against the sample size. The
true mean, m, is taken as 0, and the standard deviation as 1. The
difference between two ideally equal groups that show both
significant and non-significant results, should form a funnel-
like shape that extends to infinity along the 95% confidence
intervals (74). Taken together, these methodological issues
seriously hamper the interpretation of the meta-analysis
presented here. In conclusion, the state of our research and of
the literature to date does not permit an unequivocal and fully
satisfactory EBR determination of the best available evidence
in terms of the efficacy and effectiveness of CAM in general
and of anti-oxidants in particular for patients with sDAT.
Rather, it emphasizes several important caveats and
deficiencies of the current research that must now be
addressed, lest EBR yield to misinterpretations of the literature
and erroneous inferences for the detriment to the patients.
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A
B
Citation N1 N2 Effect NTotal PValue
61 79 79 1.848 158 .000
62 79 77 .870 156 .000
64 9 9 .238 18 .604
Fixed Combined (3) 167 165 1.226 332 .000
-4.00 -2.00 0.00 2.00 4.00
Favors No Treatment Favors Treatment
Meta Analysis: SKT
Citation N1 N2 Effect NTotal PValue
63 74 73 1.158 147 .000
64 9 9 .566 18 .225
70 409 129 .208 538 .040
Fixed Combined (3) 492 211 .443 703 .000
-4.00 -2.00 0.00 2.00 4.00
Favors No Treatment Favors Treatment
Meta Analysis: ADAS-cog
Figure 3. (A) Results from meta-Analysis of ADAS-cognitive scores (assessment of cognitive performance) for a best-case study on complementary and
alternative approaches (antioxidants). A meta-analysis was carried out to evaluate the efficacy of antioxidants in increasing the global performance of patients with
Alzheimer’s disease, as determined by scores from the ADAS-cognitive scale. Three studies on Ginkgo biloba favored treatment, whereas one study on idebenone
favored the placebo. (B) Results from meta-analysis of SKT scores (assessment of cognitive performance) for a best-case study on complementary and alternative
approaches(antioxidants). Usingdata from the SKT,a meta-analysis was carriedoutto evaluatethe efficacy of antioxidants in increasingthe globalperformanceof
patients with AD. All three studies favored the use of antioxidants to increase cognitive ability in AD patients.
Table 4. Summary of studies included in best-case study
Author Year Treatment Dosage/method of administration
60 1994 Ginkgo biloba: Extract Egb 761 80 mg daily
61 2003 Ginkgo biloba: Extract Egb 761 240 mg EGb 761 daily
62 1996 Ginkgo biloba: Extract Egb 761 240 mg EGb 761 daily
63 1997 Ginkgo biloba: Extract Egb 761 120 mg EGb 761 daily
64 1997 Ginkgo biloba: Extract Egb 761 240 mg EGb 761 daily
65 1994 Idebenone 90 mg daily
66 1998 Idebenone 90 and 120 mg daily
67 1992 Idebenone 45 mg daily
68 1997 Idebenone 30 and 90 mg daily
69 1997 Alpha-tocopherol (vitamin E) 2000 IU daily
70 2003 Idebenone 120, 240, or 360 mg Egb 761 daily
The 11 studies included in the best-case study examining antioxidants (Ginkgo biloba, idebenone and alpha-tocopherol) as a complementary and alternative
treatment for AD were then analyzed by an ‘acceptable sampling’ approach.
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